Vantage Financial Partners LLC Sells 860 Shares of Pfizer Inc. (NYSE:PFE)

Vantage Financial Partners LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,410 shares of the biopharmaceutical company’s stock after selling 860 shares during the quarter. Vantage Financial Partners LLC’s holdings in Pfizer were worth $223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Swedbank AB increased its position in shares of Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. Moloney Securities Asset Management LLC increased its position in shares of Pfizer by 37.8% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 5,785 shares in the last quarter. Cary Street Partners Asset Management LLC increased its position in shares of Pfizer by 7.0% in the 3rd quarter. Cary Street Partners Asset Management LLC now owns 18,865 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 1,238 shares in the last quarter. Hanlon Investment Management Inc. bought a new stake in shares of Pfizer in the 3rd quarter valued at $205,000. Finally, NorthRock Partners LLC increased its position in shares of Pfizer by 2.0% in the 3rd quarter. NorthRock Partners LLC now owns 25,102 shares of the biopharmaceutical company’s stock valued at $726,000 after buying an additional 497 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Guggenheim reiterated a “buy” rating and set a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.7 %

Pfizer stock opened at $25.93 on Thursday. The stock has a market cap of $146.93 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company’s 50-day moving average price is $26.31 and its two-hundred day moving average price is $27.27.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.63%. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.